ALLOB®, the Company' allogeneic osteoblastic cell therapy product, is derived from ex vivo cultured bone marrow cells of healthy adult volunteer donors. ALLOB® is currently in three Phase I/IIA proof-of-concept trials for treatment of delayed-union fractures, spinal fusion procedures and revision spinal fusion. ALLOB® received orphan drug designation for osteonecrosis from the EMA in July 2013 and from the FDA in January 2014. It also received orphan drug designation for osteogenesis imperfecta from the EMA and FDA. ALLOB® has been classified as a tissue-engineered product (non-combined) by the EMA under the ATMP regulation 1394/2007EC.
Warning: ALLOB® is an investigational product and is not yet available for sale. This website is not intended to provide medical advice or as a substitute for professional healthcare. Consult your doctor or medical provider for information about your diagnosis, treatment or condition.